Hyundai Bioscience COVID-19 Treatment Candidate Shows Efficacy with Dexamethasone

SEOUL, Dec. 7 (Korea Bizwire) — South Korean biotechnology firm Hyundai Bioscience Co. said Tuesday that the combination of its oral antiviral candidate and dexamethasone showed high efficacy in treating COVID-19 during animal testings. The company is currently re-purposing niclosamide-based CP-COV03 as a potential treatment for the COVID-19 virus. The investigative drug’s indication also includes [...]